08:50 AM EDT, 09/29/2025 (MT Newswires) -- Novartis ( NVS ) said Monday it plans to launch a direct-to-patient platform for Cosentyx in the US, effective Nov. 1.

The company said the platform will give cash-paying patients the option to buy Cosentyx, a treatment for multiple immune-mediated inflammatory diseases, at a 55% discount off the list price.

Novartis ( NVS ) said it is also looking to expand the platform to other products and to boost access and affordability for cash-paying patients in the US through a direct-to-business model.